medigraphic.com
Instituto Nacional de Salud Pública

2003, Número 5

<< Anterior Siguiente >>

salud publica mex 2003; 45 (5)


Frecuencia de anticuerpos contra el virus C de la hepatitis en pacientes con cirrosis hepática en Yucatán, México

Góngora-Biachi RA, Castro-Sansores CJ, González-Martínez P, Lara-Perera DM, Garrido-Palma J, Lara-Perera V

Idioma: Ingles.
Referencias bibliográficas: 79
Paginas: 346-350
Archivo PDF: 83.91 Kb.


RESUMEN

Objetivo. En este estudio reportamos la prevalencia de anticuerpos contra el virus C de la hepatitis (Ac-VCH) en un grupo de pacientes con cirrosis hepática (CH). Material y métodos. Se hizo un estudio prospectivo, transversal y descriptivo, de marzo de 1998 a mayo de 1999. Se estudiaron a 153 pacientes (117 (76%) hombres y 36 (24%) mujeres) con diagnóstico de CH, que eran atendidos en el Hospital General Agustín O’ Horan y en el Centro de Investigaciones Regionales Doctor Hidey Noguchi, en la ciudad de Mérida, Yucatán, México. Se aplicó un cuestionario con datos clínico-epidemiológicos y se determinó la presencia de Ac-VCH (ELISA de 2ª generación y RIBA-2 para confirmar el diagnóstico) a cada paciente. Se determinó también el antígeno de superficie de la hepatitis B (AgsHB) y anticuerpos contra el antígeno central de la hepatitis B (Anti-HBc) mediante el método de ELISA. La presencia de Ac-VCH fue relacionada con las variables epidemiológicas de los sujetos. La prevalencia de anti-HCV y la frecuencia de características se compararon entre los pacientes positivos y negativos con las pruebas de X2 y exacta de Fisher. Resultados. El 32% de los pacientes con CH (35/117 (30%) hombres y 14/36 (39%) mujeres) fueron positivos para los Ac-VCH. El alcoholismo estuvo presente en todos los hombres serorreactivos y en ninguna de las mujeres positivas (p‹ 0.001). Ningun de las variables epidemiológicas analizadas estuvo asociada con la seropositividad. Los anti-HBc se encontraron en 16% de los pacientes positivos para Ac-VCH y en 12% de los seronegativos (p=0.69). Conclusiones. La prevalencia encontrada fue mayor a los reportes previos realizados en población general de la Península de Yucatán (1.3%). La alta prevalencia de Ac-VCH en este grupo de pacientes sugiere que la CH está más frecuentemente asociada con el VCH en Yucatán, México, que con el virus B de la hepatitis. El alcoholismo probablemente actúa como un cofactor en el desarrollo de CH en los hombres.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of Hepatitis C. Ann Intern Med 2000;132:296-305.

  2. Amarapurkar D. Natural history of hepatitis C virus infection.) Gastroenterol Hepatol 2000:1 5(Suppl):105-1 10.

  3. Choo QL, Kuo G,WeinerAJ, Overby LR, Bradly DW, Hougton M. Isolation of a DNA clone derived from a blood borne non-A non-B viral hepatitis genome. Science 1989;244:359-362.

  4. Pozzato G, Kaneko S, Moretti M, Croce LS, Franzin F, Unoura M. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease.) Med Virol 1994;43:291-296.

  5. Adinolfi LE, Utili R, Andreana A,Tripodi MF, Rosario P, Mormone G et al. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2000;12:299-304.

  6. 6.Alberti A, Chemello L, Benvegnd L. Natural history of hepatitis C.J Hepatol 1999;31 (Suppl.1):17-24.

  7. González-Michaca L, Mercado A, Gamba G.Viral C hepatitis in patients with end stage renal disease. II.Viral genotypes. Rev Invest Clin 2000;52:491-496.

  8. Colombo M. Natural history and pathogenesis of hepatitis C virus-related hepatocellular carcinoma.) Hepatol 1999;31 (Suppl.1):25-30.

  9. Kato Y, Hamasaki K,Aritomi T, Nakao K, Nakata K, Eguchi K. Most of the patients with cirrhosis in Japan die from hepatocellular carcinoma. Oncol Rep 1999;6:1273-1276.

  10. Baffis V, Shrier l, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or C virus infection. Ann Intern Med 1999;131:696-701.

  11. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology 1998;3: 1206-1213.

  12. Góngora-Biachi RA, González-Martínez P, Puerto FI,Yamaguchi K, Nishimura Y, Takatsuky K. Antibodies to hepatitis C virus in people from Yucatan, Mexico. Rev Invest Clin 1992;44:284.

  13. Podolsky DK, Isselbacher KJ. Cirrhosis and alcoholic liver disease. En: Fancy AS, Brauwald E, Isselbacher KJ,Wilson JD, Martin JB, Kasper DL, Ed. Harrison's principles of internal medicine. 14th edition. Nueva York (NY): McGraw-Hill; 1998:1704-1710.

  14. Center for Disease Control. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47:10-12.

  15. Rockey DC. Hepatic fibrogenesis and hepatitis C. Semin Gastrointest Dis 2000;11:69-83.

  16. Seeff LB, Miller RN, Rabkin ChS, Buskell-Bales Z, Straley-Eason KD, Smoak BL et al. 45-years follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-111.

  17. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.Ann Intern Med 1997;127:875-881.

  18. Rodger AJ,Thomson JA,Thompson SC, Jolley D, Mijch AM, Lanigan A et al. Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: Results of a pilot study.] Gastroenterol Hepatol 1999;14:269-273.

  19. Stanta G, Croce LS, Bonin S,Tisminetzky SG, Baralle FE,Tiribelli C. Cohort effect of HCV infection in liver cirrhosis assessed by a 25 year study. J Clin Virol 2000;17:51-56.

  20. Esteban JI,Viladomiu L, González A. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989;2:294-297,

  21. Coursaget P, Simpson B, El Goulli N, Khelifa HB, Kastally R. Hepatitis

  22. C core antibody detection in acute hepatitis and cirrhosis patients from Tunisia. Path Biol 1992;40:646-648.

  23. Barnes RE, Meyer RA, Gordon SC. Prevalence of anti-HCV in cryptogenic cirrhosis in a suburban Detroit community. Am J Gastroenterol 1992;87:1001-1004.

  24. Ayoola EA, al-Mofleh IA, al-Faleh FZ, al-Rashed R, Arif MA, Ramia S. Prevalence of antibodies to hepatitis C virus among Saudi patients with chronic liver disease. Hepatogastroenterology 1992;39:337-339.

  25. Tsai JF, Chang WY,Jeng JE, Ho MS,Wang LY, Hsieh MY et al. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 1993;41:296-300.

  26. Mets T, Smitz J, Ngendahayo P, Sabbe L, Bigilimana I, Ngirabatware B. Hepatitis C virus infection in African patients with liver cirrhosis or primary hepatocellular carcinoma. Scand ) Gastroenterol 1993;28: 331-334.

  27. Rinaldi G, Saccardo F, Petrozzino MR, Bossi E, Manna MR, Monti G. Hepatitis C antibody and cryoglobulins in patients with cirrhosis and hepatocellular carcinoma. Clin Exp Rheumatol 1995;13:5161-S163.

  28. Shah HA,Jafri W, Malik I, Prescott L, Simmonds P. Hepatitis C virus (HCV) genotypes and chronic liver disease in Pakistan.J Gastroenterol Hepatol 1997;12:758-761.

  29. Berry N, Chakravarti A, Das U, Kar P, Das BC, Mathur MD. HCV seroreactivity and detection of HCV RNA in cirrhotics. Diagn Microbiol Infect Dis 1999;35:209-213.

  30. Serfaty L, Chazouilleres O, Poujol-Robert A, Morand-Joubert L, Dubois C, Chretien Y et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: Results of a case-control study. Hepatology 1997;26:776-779.

  31. Corrao G,Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27:914-919.

  32. Yamauchi M, Nakahara M, Maezawa Y, Satoh S, Nishikawa F, Ohata M et al. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C.Am J Gastroenterol 1993;88:39-43.

  33. Kwon SY,Ahn MS, Chang HJ. Clinical significance of hepatitis C virus infection to alcoholics with cirrhosis in Korea.J Gastroenterol Hepatol 2000;15:1282-1286.

  34. Hollinger FB. Factors contributing to the evolution and outcome of cirrhosis in hepatitis C. Clin Liver Dis 1999;3:741-755.

  35. Poynnard T, Moussalli J, Ratziu V, Regimbeau C, Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis 1999;3:869-881.

  36. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A et al. Interferon-rivabirin for chronic hepatitis C with and without cirrhosis:Analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999; 117:408-413.

  37. AjelloA, Freni MA, Spadaro A, Alessi N, Impellizzeri F, Console Pet al. Ten-year follow-up of patients with chronic hepatitis C treated with interferon. Hepatogastroenterology 1999;46:2447-2450.

  38. Heathcote EJ, Shiffman ML, Cooksley GE, Dusheiko GM, Lee SS, Balart L et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2001;343:1673-1680.

  39. International Interferon-a Hepatocellular Carcinoma Study Group. Effect of interferon-a on progression of cirrhosis to hepatocellular carcinoma:A retrospective cohort study. Lancet 1998;351:1535-1539.

  40. Nishiguchi S, Shiomi S, Nakatani S,Takeda T, Fukuda K,Tamori A. Prevention of hepatocellular carcinoma in patients with chronic active iepatitis C and cirrhosis. Lancet 2001;357:196-197.

  41. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of Hepatitis C. Ann Intern Med 2000;132:296-305.

  42. Amarapurkar D. Natural history of hepatitis C virus infection.) Gastroenterol Hepatol 2000:15(Suppl):105-110.

  43. Choo QL, Kuo G, WeinerA J, Overby LR, Bradly DW, Hougton M. Isolation of a DNA clone derived from a blood borne non-A non-B viral hepatitis genome. Science 1989;244:359-362.

  44. Pozzato G, Kaneko S, Moretti M, Croce LS, Franzin F, Unoura M. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease.) Med Virol 1994;43:291-296.

  45. Adinolfi LE, Utili R, Andreana A, Tripodi MF, Rosario P, Mormone G et al. Relationship between genotypes of hepatitis C virus and histopathological manifestations in chronic hepatitis C patients. Eur J Gastroenterol Hepatol 2000;12:299-304.

  46. 6.Alberti A, Chemello L, Benvegnd L. Natural history of hepatitis C.J Hepatol 1999;31 (Suppl.1):17-24.

  47. González-Michaca L, Mercado A, Gamba G. Viral C hepatitis in patients with end stage renal disease. II. Viral genotypes. Rev Invest Clin 2000;52:491-496.

  48. Colombo M. Natural history and pathogenesis of hepatitis C virus-related hepatocellular carcinoma.) Hepatol 1999;31 (Suppl.1):25-30.

  49. Kato Y, Hamasaki K, Aritomi T, Nakao K, Nakata K, Eguchi K. Most of the patients with cirrhosis in Japan die from hepatocellular carcinoma. Oncol Rep 1999;6:1273-1276.

  50. Baffis V, Shrier L, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or C virus infection. Ann Intern Med 1999;131:696-701.

  51. Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in Western countries. Hepatogastroenterology 1998;3: 1206-1213.

  52. Góngora-Biachi RA, González-Martínez P, Puerto FI, Yamaguchi K, Nishimura Y, Takatsuky K. Antibodies to hepatitis C virus in people from Yucatan, Mexico. Rev Invest Clin 1992;44:284.

  53. Podolsky DK, Isselbacher KJ. Cirrhosis and alcoholic liver disease. En: Fancy AS, Brauwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Ed. Harrison's principles of internal medicine. 14th edition. Nueva York (NY): McGraw-Hill; 1998:1704-1710.

  54. Center for Disease Control. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47:10-12.

  55. Rockey DC. Hepatic fibrogenesis and hepatitis C. Semin Gastrointest Dis 2000;11:69-83.

  56. Seeff LB, Miller RN, Rabkin ChS, Buskell-Bales Z, Straley-Eason KD, Smoak BL et al. 45-years follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-111.

  57. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-881.

  58. Rodger AJ, Thomson JA, Thompson SC, Jolley D, Mijch AM, Lanigan A et al. Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: Results of a pilot study. J Gastroenterol Hepatol 1999;14:269-273.

  59. Stanta G, Croce LS, Bonin S, Tisminetzky SG, Baralle FE, Tiribelli C. Cohort effect of HCV infection in liver cirrhosis assessed by a 25 year study. J Clin Virol 2000;17:51-56.

  60. Esteban JI, Viladomiu L, González A. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989;2:294-297,

  61. Coursaget P, Simpson B, El Goulli N, Khelifa HB, Kastally R. Hepatitis C core antibody detection in acute hepatitis and cirrhosis patients from Tunisia. Path Biol 1992;40:646-648.

  62. Barnes RE, Meyer RA, Gordon SC. Prevalence of anti-HCV in cryptogenic cirrhosis in a suburban Detroit community. Am J Gastroenterol 1992;87:1001-1004.

  63. Ayoola EA, al-Mofleh IA, al-Faleh FZ, al-Rashed R, Arif MA, Ramia S. Prevalence of antibodies to hepatitis C virus among Saudi patients with chronic liver disease. Hepatogastroenterology 1992;39:337-339.

  64. Tsai JF, Chang WY, Jeng JE, Ho MS, Wang LY, Hsieh MY et al. Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan. J Med Virol 1993;41:296-300.

  65. Mets T, Smitz J, Ngendahayo P, Sabbe L, Bigilimana I, Ngirabatware B. Hepatitis C virus infection in African patients with liver cirrhosis or primary hepatocellular carcinoma. Scand) Gastroenterol 1993;28: 331-334.

  66. Rinaldi G, Saccardo F, Petrozzino MR, Bossi E, Manna MR, Monti G. Hepatitis C antibody and cryoglobulins in patients with cirrhosis and hepatocellular carcinoma. Clin Exp Rheumatol 1995;13:5161-S163.

  67. Shah HA, Jafri W, Malik I, Prescott L, Simmonds P. Hepatitis C virus (HCV) genotypes and chronic liver disease in Pakistan. J Gastroenterol Hepatol 1997;12:758-761.

  68. Berry N, Chakravarti A, Das U, Kar P, Das BC, Mathur MD. HCV seroreactivity and detection of HCV RNA in cirrhotics. Diagn Microbiol Infect Dis 1999;35:209-213.

  69. Serfaty L, Chazouilleres O, Poujol-Robert A, Morand-Joubert L, Dubois C, Chretien Y et al. Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: Results of a case-control study. Hepatology 1997;26:776-779.

  70. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27:914-919.

  71. Yamauchi M, Nakahara M, Maezawa Y, Satoh S, Nishikawa F, Ohata M et al. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. Am J Gastroenterol 1993;88:39-43.

  72. Kwon SY, Ahn MS, Chang HJ. Clinical significance of hepatitis C virus infection to alcoholics with cirrhosis in Korea. J Gastroenterol Hepatol 2000;15:1282-1286.

  73. Hollinger FB. Factors contributing to the evolution and outcome of cirrhosis in hepatitis C. Clin Liver Dis 1999;3:741-755.

  74. Poynnard T, Moussalli J, Ratziu V, Regimbeau C, Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis 1999;3:869-881.

  75. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Hollander A et al. Interferon-rivabirin for chronic hepatitis C with and without cirrhosis: Analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999; 117:408-413.

  76. Ajello A, Freni MA, Spadaro A, Alessi N, Impellizzeri F, Console P et al. Ten-year follow-up of patients with chronic hepatitis C treated with interferon. Hepatogastroenterology 1999;46:2447-2450.

  77. Heathcote EJ, Shiffman ML, Cooksley GE, Dusheiko GM, Lee SS, Balart L et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2001;343:1673-1680.

  78. International Interferon-a Hepatocellular Carcinoma Study Group. Effect of interferon-a on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998;351:1535-1539.

  79. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A. Prevention of hepatocellular carcinoma in patients with chronic active iepatitis C and cirrhosis. Lancet 2001;357:196-197.




2020     |     www.medigraphic.com